Staff

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies…

1 week ago

The Naderi Center for Plastic Surgery and Dermatology Reveals Updated Website for Virginia and Maryland Patients

The Naderi Center's website upgrade offers comprehensive procedure insights and booking. RESTON, VIRGINIA / ACCESSWIRE / December 18, 2024 /…

1 week ago

CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization

Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly. SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 /…

1 week ago

Interactive Strength Inc. (Nasdaq:TRNR) Secures 162 Unit CLMBR Commitment and Signs Exclusive Distribution Agreement With Planet Fitness SAS for France

Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French RegionsFrance is the Second-Largest Fitness…

1 week ago

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies…

1 week ago

Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025

Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES,…

1 week ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to…

1 week ago

Rafarma pharmaceutical updates

Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA)  Dear Rafarma shareholders, We apologize for the…

1 week ago

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis testsLEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2…

1 week ago

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The…

1 week ago

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec.…

1 week ago

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

INBS Intelligent Fingerprinting Drug Screening System INBS' non-invasive, cost-effective drug screening solution NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) --…

1 week ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

1 week ago

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer…

1 week ago

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology…

1 week ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -…

1 week ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant…

1 week ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq:…

1 week ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of…

1 week ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the…

1 week ago